$ASPN

Wood River Capital, LLC sold $58.1M of ASPN

Wood River Capital, LLC sold 12,280,426 shares of ASPEN AEROGELS INC (ASPN) at $4.73 ($58.09M total) on 2026-09-23. Filed jointly with Koch, Inc. (10% owner).

Original reporting
SEC EDGAR · Wood River Capital, LLC, Koch, Inc.
Published Sep 25, 2026, 12:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ASPN
Bearish
medium confidence
Mentioned
$ASPN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASPNBearishLow
01

Why it matters

The disclosure provides fresh data on insider sentiment for ASPN.

02

Market read

First‑report insider sell of over $58M may influence short‑term trading decisions.

03

What to watch

Wood River Capital may have pre‑arranged liquidity needs unrelated to company fundamentals.

Relevance 8/10Novelty 7/10Timing: post‑market 2026‑09‑23

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ASPNBearishMedium confidence
Context

Wood River Capital sold 12,280,426 shares of Aspen Aerogels for $58.1M, leaving a zero stake.

Expected impact

Potential short-term downside pressure.

Evidence & confidence

The sale represents a significant ownership reduction and cash out of $58M.

Market effects

May affect the specialty chemicals sector if other investors follow suit.

Limited to US markets where ASPN trades.

Minimal global impact beyond the company's niche.

Counterpoint

The sale could be a portfolio rebalancing rather than a negative signal.

Key entities

  • Aspen Aerogels Inc.

    Specialty materials manufacturer.

  • Wood River Capital, LLC

    Investment manager and shareholder.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASPNMed

Aspen Aerogels Q2 Earnings Call Highlights

Aspen Aerogels (ASPN) reported Q2 gross profit of $3.3M (7% margin) after $5.3M of incremental costs tied to an April explosion at its East Providence plant. Adjusted gross profit was $8.6M (17%). GAAP net loss was $23.3M. The company is restarting the plant and expects full capacity in 1H 2027, while raising 2026 European Thermal Barrier revenue outlook to $20M-$30M.

$ASPNMed

Beerenberg Prevails in Patent Case Against Aspen Aerogels

South Korea’s Patent Court invalidated three Aspen Aerogels patents covering improved hydrophobic aerogel material, according to the company’s press release. The ruling upheld the Intellectual Property Trial and Appeal Board’s view that the patents failed patentability requirements. Beerenberg, an insulation-products firm, said the decision removes uncertainty over infringement claims.